CPI 0610
CAS No. 1845726-14-8
CPI 0610 ( CPI0610 )
Catalog No. M12851 CAS No. 1845726-14-8
CPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCPI 0610
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay.
-
DescriptionCPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay; shows remarkably selectivity, over the bromodomains of CBP, BRD9, BRPF1, PCAF, BRG1, ATAD2, TRIM24, BRD8; has an IC50 of 0.18 uM in MYC RNA expression assay; demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model.
-
SynonymsCPI0610
-
PathwayChromatin/Epigenetic
-
TargetBromodomain
-
RecptorBromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1845726-14-8
-
Formula Weight365.82
-
Molecular FormulaC20H16ClN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[e]isoxazolo[5,4-c]azepin-4-yl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Albrecht BK, et al. J Med Chem. 2016 Feb 25;59(4):1330-9.
2. Siu KT, et al. Leukemia. 2017 Jan 3. doi: 10.1038/leu.2016.355.
2. Siu KT, et al. Leukemia. 2017 Jan 3. doi: 10.1038/leu.2016.355.
molnova catalog
related products
-
ARV-771
ARV-771 is a potent BET degrader (PROTAC) in cellular models of CRPC; potently degrades BRD2/3/4 in 22Rv1 cells with DC50< 5 nM.
-
I-BET151
I-BET151 (GSK1210151A) is a potent, selective BET bromodomain inhibitor.
-
SJ830599
SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1.